# Okogen

> This newsroom holds the press releases that Okogen publishes.

## Press releases

- [Okogen Acquires Ranpirnase Assets and Intellectual Property Portfolio](https://okogen.reportablenews.com/pr/okogen-acquires-ranpirnase-assets-and-intellectual-property-portfolio): Okogen Inc., a biotechnology company developing antiviral therapeutics, today announced the acquisition of the global intellectual property portfolio and development assets for ranpirnase from Orge...
- [Okogen Announces Regulatory Submission to CDSCO for EMERALD STUDY and Appointment of New Chief Medical Officer](https://okogen.reportablenews.com/pr/okogen-announces-regulatory-submission-to-cdsco-for-emerald-study-and-appointment-of-new-chief-medical-officer): Plano, TX – April 2, 2025 – Okogen Inc., a company specializing in innovative eyecare solutions, today announced the submission of a regulatory application to the Central Drugs Standard Control Org...
- [Okogen Inc. Secures $3.3M to Advance Phase 2b Clinical Program for Pink Eye (Acute Infectious Conjunctivitis)](https://okogen.reportablenews.com/pr/okogen-inc-secures-3-3m-to-advance-phase-2b-clinical-program-for-pink-eye-acute-infectious-conjunctivitis): Plano, TX – December 11, 2024 – Okogen Inc., a company specializing in innovative eyecare solutions, today announced the successful completion of $3.3 million in financing. The funding will advance...
- [Okogen, Inc., Announces Initiation of Phase IIb Clinical Trial for Pink Eye (Acute Infectious Conjunctivitis)](https://okogen.reportablenews.com/pr/okogen-initiates-phase-iib-trial-for-pink-eye): San Diego, CA – October 31, 2023 – Okogen, an ophthalmic biotechnology company, today announced the initiation of a Phase IIb clinical trial evaluating OKG-0303 for Acute Infectious Conjunctivitis ...
- [Okogen, Inc., Announces Ophthalmology Industry Veteran Joshua Moriarty as New Chief Executive Officer](https://okogen.reportablenews.com/pr/okogen-inc-announces-ophthalmology-industry-veteran-joshua-moriarty-as-new-chief-executive-officer): San Diego, CA and Melbourne, AUS – March 8, 2022 – Okogen, an ophthalmic biotechnology company, today announced the appointment of Joshua Moriarty as the new Chief Executive Officer (CEO). Mr. Mori...
- [Safe, Effective and Dose Responsive Anti-Viral Activity of OKG-0301 in Patients with Acute Adenoviral Conjunctivitis--Phase 2 Interim Analysis Results from RUBY Clinical Trial](https://okogen.reportablenews.com/pr/safe-effective-and-dose-responsive-anti-viral-activity-of-okg-0301-in-patients-with-acute-adenoviral-conjunctivitis-phase-2-interim-analysis-results-from-ruby-clinical-trial): San Diego, CA and Melbourne, AUS – April 29, 2021 – Okogen, a clinical-stage specialty ophthalmic biotechnology company announced the interim analysis results from RUBY, the company’s Phase 2, doub...
- [Okogen Initiates Phase 2 Clinical Trial (RUBY) of OKG-0301 in Patients with Acute Adenoviral Conjunctivitis](https://okogen.reportablenews.com/pr/okogen-initiates-phase-2-clinical-trial-ruby-of-okg-0301-in-patients-with-acute-adenoviral-conjunctivitis): San Diego and Melbourne, Australia - JANUARY 31, 2019 - Okogen, a clinical-stage, specialty biotechnology company focused on developing ophthalmic therapeutics, today announced the initiation of a ...
- [Okogen, an Innovator in Treatments for Infectious Eye Diseases, Receives $10 Million Series A Funding](https://okogen.reportablenews.com/pr/okogen-raises-10-million): February 27, 2018 -- San Diego, CA -- Okogen, Inc., a developer of ophthalmic anti-infective drugs, announced $10 million in Series A funding from Brandon Capital’s Medical Research Commercialisati...

## About this newsroom

- [Newsroom home](https://okogen.reportablenews.com/)
- [Atom feed](https://okogen.reportablenews.com/feed.atom)
- [Sitemap](https://okogen.reportablenews.com/sitemap.xml)